Pre-made Tregalizumab benchmark antibody ( Whole mAb, anti-CD4 therapeutic antibody, Anti-IMD79/OKT4D Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tregalizumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tregalizumab is an immunomodulator. It is also known as BT-061. Tregalizumab binds to domain 2 of CD4, and activates Regulatory T cells (Tregs).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-594-1mg	1mg	3090	30%	2163

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Tregalizumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
INN Name	Tregalizumab
Target	CD4
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Biotest AG
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Multiple sclerosis;Plaque psoriasis;Rheumatoid arthritis
Development Tech	na